– Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery – With Portico approval, Abbott offers the industry’s most comprehensive portfolio of structural heart solutions in the U.S. ABBOTT PARK, Ill., Sept. 20, 2021 /PRNewswire/ — Abbott (NYSE: ABT) […]
Tag: Abbott
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
Acquisition builds upon Abbott’s leading vascular portfolio, adding mechanical thrombectomy devices for treating patients with peripheral blood clots ABBOTT PARK, Ill., Sept. 2, 2021 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood […]
Late-Breaking Data Shows Abbott’s Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
– New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device – Amulet device is the first and only minimally invasive option approved for LAA occlusion […]
GUIDE-HF Study Data Show Abbott’s CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure
– The GUIDE-HF study examined the potential impact of Abbott’s CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device – Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and […]
ABBOTT’S AMPLATZER™ AMULET™ DEVICE APPROVED BY FDA TO TREAT PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE
– Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn’t needed following implantation – The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with […]
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
– Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence – The new intuitive interface provides step-by-step guidance to enhance ease of use – When combined with Abbott’s Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with […]
ABBOTT INTRODUCES JOT DX™ INSERTABLE CARDIAC MONITOR, DESIGNED TO REDUCE DATA BURDEN AND IMPROVE ACCURATE DIAGNOSIS OF DIFFICULT-TO-DETECT ABNORMAL HEART RHYTHMS
– Jot Dx™ Insertable Cardiac Monitor (ICM) expands Abbott’s connected care portfolio and is the first and only device on the market with the option to control the amount of electronic data received for irregular heart rhythms, depending on the unique needs of the patient or clinic – Jot Dx™ […]
ABBOTT RECEIVES EUROPEAN AND CANADIAN APPROVAL FOR AMPLATZER™ STEERABLE DELIVERY SHEATH TO OPTIMIZE LEFT ATRIAL APPENDAGE CLOSURE PROCEDURES FOR PEOPLE AT RISK OF STROKE
– First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation – New delivery system works with Abbott’s leading Amplatzer Amulet™ LAA Occluder device to enable better access to the LAA and […]
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump
– Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD) – Access to MCS devices are critical for advanced heart failure patients and can improve […]
Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis
– Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant – The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ — Abbott (NYSE: ABT) today announced it […]



